All Stories

  1. Metabolomics in the study of alcohol use disorder: a systematic review
  2. Substance use and psychiatric comorbidities among medical inpatients: associations with length of stay, health-related quality of life, and functioning, with consideration for gender
  3. Longitudinal trajectories of tobacco and alcohol use following first or consecutive admissions for respiratory diseases
  4. Productos con CBD y su impacto en los análisis toxicológicos de orina: evidencia de una serie de 6 casos.
  5. Alcohol-associated liver disease: Natural history, management and novel targeted therapies
  6. Diagnosis and Management of Early Stages of ALD
  7. Effects of alcohol-related problems on the costs of frequent emergency department use: an economic analysis of a case–control study in Spain
  8. Efficacy of medications for the treatment of alcohol use disorder (AUD): A systematic review and meta-analysis considering baseline AUD severity
  9. Ensuring safety in cannabinoid prescriptions: A call for critical assessment
  10. Liver fibrosis screening increases alcohol abstinence
  11. Medicina de la adicción: Más allá del DSM5
  12. High-Risk Cannabis Use: A Proposal of an Operational Definition through Delphi Methodology for Scientific Consensus
  13. Another Round: Influence of Alcohol-Related Conditions and Other Drug Use-Related Disorders in Emergency Department Frequent Use – A Single-Site Matched Case-Control Study in Spain
  14. Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality
  15. Multiplatform web app (My Way Up) plus motivational interviewing for improving treatment retention in patients with onset of alcohol-related liver disease and alcohol use disorder – an example of participatory research
  16. Early Liver Transplantation in Severe Alcohol-associated Hepatitis
  17. Optimizing Digital Tools for the Field of Substance Use and Substance Use Disorders: Backcasting Exercise
  18. Reply: Medications promoting abstinence in alcohol-associated cirrhosis
  19. Psychological interventions to treat alcohol use disorder in patients with liver disease
  20. Medications for alcohol use disorder promote abstinence in alcohol-associated cirrhosis: Results from a systematic review and meta-analysis
  21. Social disparities in alcohol's harm to others: evidence from 32 European countries
  22. The socioeconomic profile of alcohol use in Europe: findings from 33 European countries
  23. The impact of legal cannabis availability on cannabis use and health outcomes: A systematic review
  24. Unrecorded alcohol use in 33 European countries: Analyses of a comparative survey with 49,000 people who use alcohol
  25. Measuring cannabis quantities in online surveys: A rapid review and proposals for ways forward
  26. Vickybot, a Chatbot for Anxiety-Depressive Symptoms and Work-Related Burnout in Primary Care and Health Care Professionals: Development, Feasibility, and Potential Effectiveness Studies
  27. La importancia de los patrones de consumo: Diseño de una encuesta que permita evaluar daño relacionado al consumo de cannabis
  28. Editorial: Using digital solutions for Brief Interventions in Alcohol, Tobacco, other drug use, and gambling: From the present to the future
  29. Synthetic Cannabinoids and Cannabis: How the Patterns of Use Differ: Results from the European Web Survey on Drugs
  30. “Doctor, Can I Drink an Alcohol-Free Beer?” Low-Alcohol and Alcohol-Free Drinks in People with Heavy Drinking or Alcohol Use Disorders: Systematic Review of the Literature
  31. Tailoring an evidence-based clinical intervention and training package for the treatment and prevention of comorbid heavy drinking and depression in middle-income country settings: the development of the SCALA toolkit in Latin America
  32. Telemedicine in the treatment of addictions
  33. The iCannTookit: a consensus‐based, flexible framework for measuring contemporary cannabis use
  34. Revisión sistemática sobre el manejo clínico del dolor crónico y el trastorno por uso de opioides simultáneo
  35. Reduced alcohol consumption during the COVID-19 pandemic: Analyses of 17 000 patients seeking primary health care in Colombia and Mexico
  36. The iCannToolkit: a tool to embrace measurement of medicinal and non‐medicinal cannabis use across licit, illicit and cross‐cultural settings
  37. Changes in alcohol use during the COVID‐19 pandemic in Europe: A meta‐analysis of observational studies
  38. Clozapine toxicity and coronavirus disease 2019: A case report
  39. Training primary health care providers in Colombia, Mexico and Peru to increase alcohol screening: Mixed-methods process evaluation of implementation strategy
  40. An Eight-Year Followup Study after Heart Transplantation: The Relevance of Psychosocial and Psychiatric Background
  41. A randomized controlled non-inferiority trial of primary care-based facilitated access to an alcohol reduction website (EFAR Spain)
  42. Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates
  43. Standard units for cannabis dose: Why is it important to standardize cannabis dose for drug policy and how can we enhance its place on the public health agenda?
  44. The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use
  45. Changes in Alcohol Consumption during the COVID-19 Pandemic Are Dependent on Initial Consumption Level: Findings from Eight European Countries
  46. Early, Chronic, and Acute Cannabis Exposure and Their Relationship With Cognitive and Behavioral Harms
  47. Rehabilitation Gaming System for Alcohol-Related Cognitive Impairment: A Pilot Usability Study
  48. Validation of the Alcohol Smoking and Substance Involvement Screening Test (ASSIST) in acute psychiatric inpatients
  49. Supporting Future Cannabis Policy – Developing a Standard Joint Unit: A Brief Back-Casting Exercise
  50. Mid and long-term effects of a SBIRT program for at-risk drinkers attending to an emergency department. Follow-up results from a randomized controlled trial.
  51. Factors Affecting Quality of Life in Liver Transplant Candidates: An Observational Study
  52. Impact of Training and Municipal Support on Primary Health Care–Based Measurement of Alcohol Consumption in Three Latin American Countries: 5-Month Outcome Results of the Quasi-experimental Randomized SCALA Trial
  53. Relación entre las motivaciones para consumir y el consumo problemático de cannabis
  54. Psychiatric Clinical Profiles and Pharmacological Interactions in COVID-19 Inpatients Referred to a Consultation Liaison Psychiatry Unit: a Cross-Sectional Study
  55. Perceived appropriateness of alcohol screening and brief advice programmes in Colombia, Mexico and Peru and barriers to their implementation in primary health care – a cross-sectional survey
  56. Motivational Interviewing for Cannabis Use Disorders: A Systematic Review and Meta-Analysis
  57. Mortality involving New Psychoactive Substances across Europe, 2016-2017
  58. Cannabis use the week before admission to psychiatric in-patient service as a marker of severity
  59. COVID-19 inpatients with psychiatric disorders: Real-world clinical recommendations from an expert team in consultation-liaison psychiatry
  60. A systematic review of treatments for alcohol-related cognitive impairment: lessons from the past and gaps for future interventions
  61. Active Smoking Before Liver Transplantation in Patients with Alcohol Use Disorder: Risk Factors and Outcomes
  62. e-INEBRIA Special Interest Group Roadmap for Best Practices for Research on Brief Digital Interventions for Problematic Alcohol and Illicit Drug Use
  63. “The post-COVID era”: challenges in the treatment of substance use disorder (SUD) after the pandemic
  64. Implementing primary healthcare-based measurement, advice and treatment for heavy drinking and comorbid depression at the municipal level in three Latin American countries: final protocol for a quasiexperimental study (SCALA study)
  65. Remote Monitoring Telemedicine (REMOTE) Platform for Patients With Anxiety Symptoms and Alcohol Use Disorder: Protocol for a Case-Control Study
  66. e-INEBRIA Special Interest Group Roadmap for Best Practices for Research on Brief Digital Interventions for Problematic Alcohol and Illicit Drug Use (Preprint)
  67. The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms
  68. Safety of nalmefene for the treatment of alcohol use disorder: an update
  69. Remote Monitoring Telemedicine (REMOTE) Platform for Patients With Anxiety Symptoms and Alcohol Use Disorder: Protocol for a Case-Control Study (Preprint)
  70. Translation, adaptation, and reliability of the Stanford Integrated Psychosocial Assessment for Transplantation in the Spanish population
  71. Factors affecting engagement of primary health care professionals and their patients in facilitated access to online alcohol screening and brief intervention
  72. Prediction of Alcohol Relapse Among Liver Transplant Candidates With Less Than 6 Months of Abstinence Using the High‐Risk Alcoholism Relapse Score
  73. Digital brief interventions for risky drinkers are not the panacea: A pilot study exploring barriers for its implementation according to professionals’ perceptions
  74. Treatment retention in a specialized alcohol programme after an episode of alcoholic hepatitis: Impact on alcohol relapse
  75. Call for Action: Benzodiazepine Prescription Prevalence Analysis Shows Off-Label Prescription in One in Eleven Citizens
  76. Role of Alcohol and Drug Detection by Regular Urine Sample Testing in pre-transplant evaluation for Alcohol Liver Disease
  77. Posverdad del consumo de cannabis: de regreso a la medicina basada en la evidencia
  78. Constituyentes psicoactivos del cannabis y sus implicaciones clínicas: una revisión sistemática
  79. Effectiveness of a Specialized Brief Intervention for At-risk Drinkers in an Emergency Department: Short-term Results of a Randomized Controlled Trial
  80. Quantitative Criteria to Screen for Cannabis Use Disorder
  81. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival
  82. Barriers to implement screening for alcohol consumption in Spanish hypertensive patients
  83. The Standard Joint Unit
  84. Risky Drinkers Underestimate their Own Alcohol Consumption
  85. Self-management and Shared Decision-Making in Alcohol Dependence via a Mobile App: a Pilot Study
  86. Working on a Standard Joint Unit: A pilot test
  87. Definitions of Risky and Problematic Cannabis Use: A Systematic Review
  88. El alcoholismo y su abordaje desde una perspectiva ciudadana
  89. Implementing referral to an electronic alcohol brief advice website in primary healthcare: results from the ODHIN implementation trial
  90. Editorial: Brief Interventions for Risky Drinkers
  91. Alcohol consumption in upper aerodigestive tract cancer: Role of head and neck surgeons' recommendations
  92. A randomised controlled non-inferiority trial of primary care-based facilitated access to an alcohol reduction website (EFAR Spain): the study protocol
  93. Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments
  94. Nalmefene and its use in alcohol dependence
  95. Cannabinoid Hyperemesis Syndrome